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Increase of enzyme activity through specific covalent 
modification with fragments  
J.F.Darby,a M. Atobe,a,b J.D. Firth,a P.Bond,a G.J. Davies,a P. O’Briena and R. E. Hubbard*a,c 
Modulation of enzyme activity is a powerful means of probing cellular function and can be exploited for diverse 
applications. Here, we explore a method of enzyme activation where covalent tethering of a small molecule to an enzyme 
can increase catalytic activity (kcat/KM) up to 35-fold. Using a bacterial glycoside hydrolase, BtGH84, we demonstrate how 
small molecule "fragments", identified as activators in free solution, can be covalently tethered to the protein using 
Michael-addition chemistry. We show how tethering generates a constitutively-activated enzyme-fragment conjugate, 
which displays both improved catalytic efficiency and increased susceptibility to certain inhibitor classes. Structure guided 
modifications of the tethered fragment demonstrate how specific interactions between the fragment and the enzyme 
influence the extent of activation. This work suggests that a similar approach may be used to modulate the activity of 
enzymes such as to improve catalytic efficiency or increase inhibitor susceptibility. 
Introduction 
In nature, direct binding of an enzyme to another molecule to 
increase catalytic activity has evolved as a control mechanism 
in many biological systems; either through binding of another 
protein molecule (such as cyclin binding to cyclin-dependent 
kinases1, co-chaperones binding to Hsp902 and GAPs binding 
to K-Ras3) or less frequently through binding of an endogenous 
small molecule (such as nicotinamide binding to sirtuins4 and 
AMP binding to AMP-activated kinase5). There have, however, 
been relatively few examples where such activation 
mechanisms have been exploited "artificially" using small 
molecules;6 notable exceptions being activators of SIRT17, 
glucokinase8 and ALDH29. For those artificial systems where 
mechanistic insight has been obtained, the activators 
manipulate catalysis through affecting allosteric regulation8, 
conformational change10, enzyme dynamics11, 12 or substrate 
binding9. Enzyme activation with small molecules via these 
mechanisms often requires that the activator be present in 
excess of the enzyme concentration. There are some studies 
which demonstrate that this limitation can be overcome 
through covalent modification.  Work from nearly 20 years ago 
on subtilisin Bacillus lentus demonstrated activation from 
chemical modification of a cysteine introduced in the substrate 
binding site13, 14.  A different strategy is to screen for 
disulphide containing compounds that react with natural or 
introduced cysteine residues15, a tethering approach which has 
in one instance led to increase in activity of a kinase16. 
Although these studies demonstrate that covalent attachment 
of a synthetic molecule to an enzyme can lead to increased 
activity, they depend on prior knowledge of where to 
introduce the covalent ligand. In the present work we 
demonstrate a rational approach to designing such covalent 
modifications through structure-guided incorporation of small 
molecule activators at a site identified from fragment 
screening. 
We have used a glycoside hydrolase from Bacteroides 
thetaiotaomicron, BtGH8417, as a model system to explore 
activation by small molecules. The catalytic domain of BtGH84 
is homologous to that of the human enzyme O-GlcNAcase 
(OGA) which removes the N-acetylglucosamine post-
translational modification on serine and threonine amino 
acids18 and BtGH84 itself indeed functions as a generic 
hexosaminidase19. BtGH84 has been a useful model for 
analysis of compounds such as PUGNAc (1)20 and thiamet-G 
(2)21, and the utility of this model has recently been confirmed 
by publication of the first hOGA crystal structures22-24. These 
compounds modify the O-GlcNAc status in cells, with thiamet-
G demonstrating impact on a variety of biological processes 
and with therapeutic potential, particularly for 
neurodegeneration25-27. Previously28, we described the unusual 
activation of BtGH84 by small molecules. We used ligand-
observed NMR spectroscopy to identify small organic 
molecules (fragments) which bound to BtGH84. Most were 
inhibitory and competitive with PUGNAc but some, such as 3, 
were non-competitive. Furthermore, 3 not only enhanced the 
binding of PUGNAc, but also increased the catalytic activity of 
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the enzyme through a non-essential activator mechanism29. 
Subsequent optimisation and characterisation of the 
fragments (including a crystal structure – PDB code: 4UR9) 
demonstrated that the fragments bind close to the active site 
and appear to stabilise an active “loop-closed” conformation. 
As with BtGH84, a large number of enzymes perform catalysis 
with mechanisms that exploit conformational changes30. 
Fragment-based activator discovery could therefore be an 
approach to identify compounds that affect conformational 
change, to probe the biological role of an enzyme in the cell, as 
a potential therapeutic agent (as with glucokinase31) but also 
to increase the activity of enzymes used in biotechnological or 
industrial processes. Although there is extensive work in 
optimising conditions for the activity of industrial enzymes 
(e.g. pH, solvents, and immobilisation as reviewed in 32, 33), 
there have not been reports on identifying activators. Such an 
approach using non-covalent compounds may indeed not be 
commercially feasible, due to the cost of the activator 
compound required, which would be expensive to recover or 
separate from the products of the catalytic process – 
analogous to some of the challenges surrounding cofactor-
dependent industrial biocatalysts34. However, chemical 
attachment of the activator to the enzyme could give 
increased activation and circumvent the issues of activator 
recovery and separation. This would provide an alternate 
strategy to current techniques, such as directed evolution, to 
engineer improvements in the performance of an industrial 
enzyme.  
Here, we validate the covalent-activation strategy using a 
tethering approach established for irreversible inhibition35. We 
describe the design, synthesis and characterisation of 
fragment activators modified to attach covalently to a specific 
attachment site (cysteine) introduced into BtGH84 and show 
that specific interactions made by the small molecule affect 
the catalytic activity. This model system demonstrates that 
tethering of a fragment can lead to a modified enzyme with 
significantly enhanced activity. The work provides the 
foundation for a combined fragment screening and tethering 
approach as a general strategy to be considered for enzyme 
optimisation in future. This strategy may find use in the 
activation of enzymes used for industrial processes or to 
enhance the effects of pharmacological small-molecule 
activators. 
Results 
Design and synthesis of tethering compounds and mutant BtGH84 
Previous work had identified small molecule activators of 
BtGH8425, including activator 3. Here, we have designed 
fragment tethers using the previously solved crystal structure 
of 3 and PUGNAc (2) bound to BtGH84 (see Figure 1, PDB code: 
4UR9), in order to conjugate the activators to the enzyme. We 
noted that position 2 on the quinazoline ring of 3 presented a 
vector towards Cγ of Y550, positioned on a flexible loop above 
the enzyme active site. We designed tethering compound 4, 
which we predicted would undergo Michael-style conjugate 
addition to the acrylamide from the free cysteine thiol 
introduced by the mutation Y550C. Modelling of the resulting 
linker showed that the tethered quinazoline ring should be 
able to occupy the position observed in the crystal structure 
without significant linker strain. In order to prevent 
promiscuous off-site reactivity, we analysed the positions of 
the three other free cysteine residues in BtGH84. C420 and 
C654 are solvent exposed whilst the third, C278, is buried close 
to the binding site and is likely inaccessible to modification. In 
order to direct reactivity of 4 with BtGH84 to the desired site, 
a triple mutant (Y550C, C420S, C654S, hereafter BtGH84_TM – 
signifying triple mutant) was expressed. Enzymatic activity of 
this variant was reduced, with the kcat/KM lowered to 60% of 
that of wild-type BtGH84 (Table 1). 
The designed covalent tether was attached to BtGH84 in 
aqueous solution by combining BtGH84_TM with an excess of 
4 (synthesised via the Curtius rearrangement as shown in 
Supplementary Scheme S1). This reaction resulted in complete 
conversion to the conjugate product, BtGH84_TM-4, within 2-4 
hours. This conversion was confirmed by intact protein ESI 
mass spectrometry (Supplementary Data) which showed a 
species of the expected molecular weight for BtGH84_TM-4, 
with no BtGH84_TM observed in the sample. To corroborate 
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this the product was further characterised using Ellman’s 
reagent32 (5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB), an 
accurate colorimetric method to quantify free thiol 
concentration present in a sample. BtGH84_TM-4 was 
denatured and the thiol concentration shown to be equivalent 
to one thiol per molecule of BtGH84_TM-4, whereas 
unlabelled BtGH84_TM contained two thiols per molecule 
(Supplementary Figure 1). These results demonstrate complete 
conversion to BtGH84_TM-4 at the desired site since any 
reactivity at the buried C278 should show a mixture of mono- 
and di-substituted product evident in either the mass 
spectrometry or thiol quantification data. 
In order to assess the impact of the tether on catalytic 
efficiency, the activity of the resultant BtGH84_TM-4 
conjugate was determined by conversion of the synthetic 
substrate 4-methylumbelliferyl N-acetyl-β-D-glucosaminide 
(4MU-GlcNAc, Figure 2a) to the fluorescent 4-
methylumbelliferone (4MU) product. As shown through 
Michaelis-Menten kinetics, Figure 2b, there is a dramatic 
change in activity both in terms of the Michaelis constant (KM) 
and maximum velocity (Vmax) of the covalently modified 
enzyme BtGH84_TM-4 towards this substrate. Using the 
kcat/KM as a quantification of enzyme activity, BtGH84_TM-4 
demonstrated a 10-fold increase over the activity of wild-type 
BtGH84 and an 18-fold increase over the parent BtGH84_TM 
enzyme, Table 1. 
We hypothesized that covalent tethering might also increase 
the affinity for inhibitors with chemical similarity to the 
substrate used (which would also further increase the utility of 
the tethering approach for exploring biological processes). The 
BtGH84 inhibitor PUGNAc (2) contains a hydrophobic phenyl 
ring linked to N-acetyl-β-D-glucosaminide, similar to the 
structure of the 4MU-GlcNAc substrate – a hydrophobic 
aglycone linked to the protein binding sugar (Supplementary 
Figure 8). We therefore assessed the binding of PUGNAc in the 
presence and absence of the covalent tether using isothermal 
titration calorimetry (ITC). The BtGH84_TM-4 conjugate binds 
PUGNAc with a Kd of 0.17 µM; a more than 10-fold increase in 
affinity from BtGH84_TM, Figure 2c and 2d, showing that the 
presence of the tether does indeed increase the binding 
affinity of PUGNAc. 
In order to understand the mode of action and binding, X-ray 
crystal structures of the tethered BtGH84_TM-4, and 
structures of BtGH84_TM-4 with the active site occupied by 
inhibitors thiamet-G (1) and PUGNAc (2), were determined by 
X-ray crystallography at resolutions of 1.8, 2.0 and 2.15 Å 
respectively, Supplementary Table 1. The structure of 
BtGH84_TM-4 in the absence of an inhibitor shows density for 
the tethered compound 4, with the best model for this density 
positioning 4 rotated away from the active site, Supplementary 
Figure 4, compared to the position observed for the non-
covalent activator 3 (Supplementary Figure 5). In the absence 
of an inhibitor in this structure the active site is occupied by 
ethylene glycol. 
The structure of BtGH84_TM-4 with thiamet-G, an inhibitor 
lacking a hydrophobic aglycone with which the quinazoline 
ring can interact, shows clear electron density for 4, but again 
with some uncertainty over the precise position of the 
fragment, Supplementary Figures 4 and 5. The flexible linker 
apparently allows the fragment to occupy multiple 
conformations in these cases where there are no constraining 
interactions. In comparison to the apo structure, the best 
fitting position of the tether in the thiamet-G complex is 
flipped by 180°, but remains positioned away from the active 
site. 
Excitingly, obtaining a structure of BtGH84_TM-4 in complex 
with PUGNAc (2) shows the tether clearly in a position 
consistent with the model in Figure 1 based on the non-
covalent complex of BtGH84, 3 and PUGNAc. The presence of 
the inhibitor aglycone locks the flexible modification of 4 at 
Y550C into a single position and the electron density of the 
modification is well defined, Figure 3b. The quinazoline ring is 
seen stacking onto Y137 and pointing towards the active site, 
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with the amide linker coordinating a water molecule with 
Q551. The varying position of the tether in these three 
structures demonstrates the flexibility of the linker, however 
the fragment is in each case centred on the π-stacking 
interaction with Y137 (Supplementary Figure 9). This led us to 
consider how the specific interactions of the tether contribute 
towards the effects seen on the enzymatic activity and 
inhibitor binding of BtGH84. 
 
Table 1 

Investigating the chemistry of the covalent modification 
In order to dissect the role of the specific chemistry of the 
BtGH84_TM-4 conjugate in altering enzyme activity, we 
designed and synthesised a small family of analogues of 4 to 
interrogate specific interactions observed between the non-
covalent activator 3 and BtGH84, and which are also seen in 
the BtGH84_TM-4 PUGNAc-bound structure. The π-stacking of 
the activators 3 and 4 onto Y137 shown in Figures 1 and 3b 
may promote formation of the H-bond from Y137 to the 
catalytic aspartate D243. If this interaction is critical to the 
activation mechanism a simplified pyrimidine activator such as 
5 should retain a good degree of activation. Alternatively, if a 
direct interaction between the substrate aglycone and the 
fragment is important, removing the fused phenyl ring from 
the activator should reduce enzyme activation. We also 
considered if we retained the fused ring whether other 
interactions between 3 and BtGH84 could be related to the 
activation effects. 
One such interaction observed in the X-ray crystal structures is 
formed between the nitrogen at position 1 of the quinazoline 
ring and R347, for compound 3, and water-mediated 
interactions with the linker in the case of 4 (Figure 3b). 
Compounds 6 and 7 remove the two ring nitrogens at positions 
1 and 3 respectively, to explore if either is critical to enzyme 
activation. Further interactions identified in our previously 
Protein - BtGH84  BtGH84_TM 
Modification - none none 4 5 6 7 8 9 10 
Vmax µM/min 200 ± 14 380 ± 20 415 ± 9 69 ± 2 510 ± 60 250 ± 6 320 ± 60 305 ± 85 320 ± 35 
Km µM 1460 ± 220 4680 ± 220 280 ± 10 370 ± 70 190 ± 2 400 ± 25 200 ± 10 145 ± 18 230 ± 46 
kcat 1/s 67 ± 5 127 ± 6 138 ± 3 23 ± 1 171 ± 21 82 ± 2 108 ± 19 102 ± 28 107 ± 12 
kcat/Km 1/Msec 
46000 ± 
5900 
27200 ± 
2460 
498200 ± 
29400 
64200 ± 
10900 
888000 ± 
99000 
207000 ± 
19000 
541000 ± 
70100 
694000 ± 
110000 
471000 ± 
143000 
Fold WT 1.0 0.6 ± 0.05 10.8 ± 0.6 1.4 ± 0.2 19.3 ± 2.1 4.5 ± 0.4 11.7 ± 1.5 15.1 ± 2.4 10.2 ± 3.1 
Fold Parent n/a n/a 18.3 ± 1.1 2.4 ± 0.4 32.6 ± 3.6 7.6 ± 0.7 19.9 ± 2.6 25.5 ± 4.0 17.3 ± 5.3 
Kd (PUGNAc) nM 2500 ± 200 2600 ± 110 170 ± 10 830 ± 530 520 ± 200 2550 ± 580 77 ± 7.7 780 ± 135 ND 
Kd    
(thiamet- G) 
nM 50 52 ± 5.7 50 ± 7.6 45 ± 16 51 ± 10 73 ± 21 44 ± 15 59 ± 27 75 ± 16 
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published work25, such as changes to the ethoxy group at 
position 4, led to improved activation. Compound 8 is designed 
to mimic these improved non-covalent activators. We also 
considered whether mobility of the tether between the 
varying positions seen in the X-ray crystal structures could 
promote or hinder activation. Compounds 9 and 10 attempt to 
coordinate the water seen H-bonded to H433 in the structure 
of BtGH84_TM-4, potentially stabilising the conformation seen 
in this structure and reducing linker mobility.  
Modification of BtGH84_TM with the acrylamide containing 
fragments 5-10 using the same protocol as 4 resulted in 
incomplete conversion to the desired products. This is perhaps 
due to reduced reactivity of these compounds or weaker 
binding to the enzyme activator site. Tethering conditions 
were modified by altering the pH of the reaction buffer to 
affect the protonation state of Y550C – changing the 
proportion of the reactive thiolate anion. Increasing the pH led 
to better conversion to the modified protein, with over 90% 
conversion in 2 hours at pH 7.8 (Supplementary Figure 1). 
Labelling BtGH84_TM overnight at pH 7.8 with 5-10 led to 
complete conversion to the desired products as demonstrated 
by thiol quantification and mass spectrometry (Supplementary 
Figure 1 and Supplementary Data). 
Investigating the mechanism of activation 
Successful production of homogenous samples of tether 
labelled BtGH84_TM permitted us to obtain Michaelis-Menten 
kinetic parameters, Table 1, to quantify activation for each 
modification. Activity of BtGH84_TM-5 was significantly lower 
than seen for BtGH84_TM-4, with only a small 1.4-fold 
increase in kcat/KM, compared to wild-type BtGH84. The lack of 
activation with this tether suggests that the Y137 π-stacking 
interaction is not sufficient for activation and perhaps had 
limiting effects on the Vmax of BtGH84_TM. In contrast, the 
tethers designed to investigate the importance of the nitrogen 
position in the quinazoline ring, BtGH84_TM-6 and 
BtGH84_TM-7, were both able to increase activity above that 
of the wild-type enzyme. These conjugates showed 18 and 4-
fold increases in kcat/KM over BtGH84 respectively. The much 
higher activity of BtGH84_TM-6 gives a clear preference for 
the nitrogen position that retains the interactions observed in 
the X-ray crystal structures; in fact BtGH84_TM-6 
demonstrated the highest activity of the fragment modified 
enzymes investigated in this work. The tether based on the 
compounds showing the highest activation in our previous 
work on non-covalent activators25, BtGH84_TM-8 (crystal 
structure shown in Figure 3c), increased kcat/KM 11-fold, a 
similar change to BtGH84_TM-4. This suggests that when 
tethered to BtGH84 the morpholino and thiophene groups 
have little effect on the activating behaviour of the 
modification. BtGH84_TM-9 and BtGH84_TM-10 were 
intended to coordinate a water molecule with H433.  These 
modifications increased enzyme kcat/KM by 15 and 10-fold 
respectively, a significant change in activity but not an 
improvement over BtGH84_TM-6. The varying activities of 
each of these enzyme-fragment conjugates demonstrated that 
specific interactions between the modification and the protein 
are required for activation. All the activator modifications 
retain the ability to form a π-stacking interaction with Y137, 
potentially affecting the behaviour of this residue in BtGH84 
catalysis. 
Inspection of the 3-D structure of the catalytically competent 
conformation of BtGH84 (Figure 3b) indicated an H-bond 
between Y137 and D243. We hypothesised that stabilization of 
this interaction might contribute to the mechanism of 
fragment activation. To test this hypothesis, we generated 
variants of BtGH84 and BtGH84_TM containing a Y137F 
mutation, BtGH84_Y137F and BtGH84_QM (signifying 
quadruple mutant) respectively, which will not have an H-bond 
to the catalytic D243. Michaelis-Menten kinetic analysis of 
these variants, Supplementary Table 2, showed reduced 
activity when compared to BtGH84 and BtGH84_TM 
demonstrating that maintaining the Y137 to D243 interaction 
contributes to efficient catalysis in the wild-type enzyme.  
In order to understand whether activation of BtGH84 also 
depends on stabilisation of this key interaction we generated 
tether modified versions of BtGH84_QM in an analogous 
manner to BtGH84_TM. The tether variants of BtGH84_QM 
showed increases in activity, measured as kcat/KM, over the 
parent enzyme BtGH84_QM comparable to those seen for 
BtGH84_TM conjugates when compared to BtGH84_TM, 
Figure 4a and Supplementary Table 3. This suggests that the 
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interaction between Y137F and D243 is not critical to the 
activation mechanism. As an alternative explanation we 
considered whether direct interaction between the substrate 
and activator could be responsible for increasing activity. 
Each of the covalent modifications investigated in the current 
work, with the exception of 5, contain an aromatic ring that 
can be orientated towards the active site and form a potential 
interaction with the aglycone group of an inhibitor or a 
substrate. To investigate this interaction we considered that 
PUGNAc could be an approximate surrogate for 4MU-GlcNAc 
based on structural similarity (Supplementary Figure 8). We 
measured the affinity of BtGH84_TM-fragment conjugates for 
PUGNAc using ITC, Table 1, Supplementary Table 4 and 
Supplementary Figure 3. There is correlation between affinity 
and degree of activation for some of the modifications, 
although the enzyme modified with the best activator, 6, binds 
PUGNAc some 7-fold more weakly than when modified with 
the weaker activator, 8, perhaps because the large morpholino 
substituent of 8 is more suited to interact with PUGNAc than 
with 4MU-GlcNAc.   In contrast, affinities of thiamet-G, which 
lacks a hydrophobic aglycone group, for the BtGH84-fragment 
conjugates, showed no correlation, Table 1.  
These changes in binding affinity for PUGNAc suggest that 
similar changes in 4MU-GlcNAc affinity should lead to an 
increase in the catalytic rate. One possible explanation is that 
the direct interaction between substrate and tether 
modification could alter the pH dependency of enzyme activity 
by improving the ability of 4MU to act as the leaving group. To 
investigate this, we measured the modified BtGH84_TM 
enzyme activity across a 12-point pH range, generating pH-
activity profiles for each of the BtGH84_TM conjugates, Figures 
4b and 4c (full data shown in Supplementary Figure 7). While 
the changes in the pH optima are moderate, the tethered 
enzymes that showed strong activation such as with 6, 9 and 
10 have a higher pH optima of 6.25-6.5, than the unconjugated 
enzyme or enzyme conjugated with poor activating 
modifications such as 5 or 7, which range from pH 5.5-6.0. In 
addition the degree of activation seen at pH values above the 
optima is greater than at the pH optima, Supplementary Figure 
7. This slight change in pH preference suggests that the tethers 
may affect the protonation of the leaving group at high(er) pH 
in addition to altering the binding affinity of the substrate. This 
data provides the first steps to understanding the mechanism 
of BtGH84 activation by covalent modification for the 4MU-
GlcNAc.   
Discussion 
Many different protein engineering approaches to changing 
biocatalyst activity have been developed over the past 30 
years with applications including improved enzymes for 
production of pharmaceuticals36, fine chemicals37, lab-based 
biocatalysis for synthetic chemistry38 and for use in industrial 
processes such as biofuel generation39. Perhaps the most 
powerful and widely used approach is directed evolution, 
where random mutagenesis by error-prone PCR generates 
extremely large libraries of enzyme variants40, 41. Improved 
enzymes are identified either by selection based upon survival 
advantage or by high-throughput methods of analysing 
activity42. Such directed evolution is powerful, but can only 
explore the limited chemistries available through the genetic 
code. There has been some work exploring incorporation of 
unnatural amino acids acids using synthetic biology methods43, 
but the scope is limited by the number of modified tRNAs 
available.  
In comparison to these biological approaches, chemical 
modification methods are less common. PEGylation of 
industrial enzymes has been used to improve physico-chemical 
properties, as reviewed in44, and there was early exploration of 
chemical modification of mutant subtilisin. However, such 
small molecule approaches have not been widely used. 
Fragment-based approaches are now well established for lead 
discovery in the pharmaceutical industry45 and the work 
presented here demonstrates how these can provide an 
alternative method to expand and alter the chemistry of 
enzymes.  
We have demonstrated the design of a covalent tether to 
optimise the previously-observed25 binding mode of a non-
covalent activator of BtGH84. Remarkably, not only was the 
binding mode retained but the effects of the modification on 
enzyme activity were more profound than those seen with 
non-covalent activators, with a greater than 10-fold (up to 35 
fold) increase in specific activity for the most active enzyme-
fragment conjugates. Only limited optimisation of the 
chemistry of the modification was carried out so there is 
potential for even larger effects. 
We have shown that the mechanism of activity enhancement 
is consistent with a direct interaction between substrate and 
the modification – effectively allowing binding site 
optimisation for the substrate leaving group aglycone. 
Furthermore, given that the activation is via the aglycone and 
not the "-1 subsite" sugar, covalent activator modifications 
similarly improve the binding affinity of an "aglycone-
containing" inhibitor PUGNAc, but have no effect on a sugar 
mimicking inhibitor such as thiamet-G. Perturbation of enzyme 
dynamics and conformation of the "catalytic loop" by the 
modifications, may also contribute to the observed effects.  
Our results also demonstrate that the degree of activation is 
dependent on subtle combinations of interactions that can be 
achieved between activator, enzyme and substrate.  This 
suggests that the initial non-covalent fragment activator 
should be identified in assays with the target substrate.  
Further work on the mechanism of activation will require 
consideration of enzyme dynamics and the impact of the 
modifications on the rate limiting chemical steps. 
Conclusion 
In this study we have demonstrated proof of principle for a 
fragment-based discovery approach to enzyme engineering 
that could prove complementary to directed evolution and de 
novo design. The general strategy is to use sensitive 
biophysical methods to screen relevant targets to identify 
weak binding fragments. These fragment hits are then 
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assessed in appropriate assays to identify fragments that bind 
allosterically or increase enzyme activity. If possible, the 
fragments are optimised at this stage to identify improved 
activity. Crystal structures of the bound fragments can then 
inform the design of linkers and the design of further chemical 
modifications to improve the activator as well as to aid 
introduction of appropriate synthetic handles on the enzymes.  
As with fragment based discovery of inhibitors, we think this 
approach to enzyme engineering may have general 
applicability, not only for improving the performance of 
enzymes, but also for developing probes to investigate how 
modulating enzyme activity can impact on studies of cell 
biology, either through increasing activation or improving the 
affinity of inhibitors. 
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